Physician profile
Ming Chen
NPI 1376621318
$12,554.74
in general payments reported to CMS, 2019-2025
21 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,690 · 2020: $312 · 2021: $1,361 · 2022: $1,016 · 2023: $3,196 · 2024: $2,681 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,115 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,115.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,060.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $3,602.66 | 2022-2024 | Vyzulta, Stellaris, Lotemax |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,641.89 | 2019-2020 | |
| Alcon Vision LLC | $1,560.83 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Allergan, INC. | $1,483.23 | 2019-2021 | |
| Abbvie INC. | $917.98 | 2022-2025 | Xen Glaucoma Treatment System, Alphagan P, Lumigan |
| Amgen INC. | $536.69 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $391.79 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Dompe US, INC. | $356.95 | 2022-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $331.69 | 2019-2024 | Eylea, Eylea Hd |
| Genentech USA, INC. | $328.67 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $230.79 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $205.49 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $163.12 | 2019-2024 | Cequa |
| Eyevance Pharmaceuticals LLC | $155.42 | 2019 | |
| Horizon Therapeutics Plc | $134.28 | 2022-2023 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $123.56 | 2022 | |
| Rxsight INC | $119.56 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $113.29 | 2019 | |
| Apellis Pharmaceuticals, INC. | $112.48 | 2024 | Syfovre |
| Shire North American Group INC | $24.96 | 2019 | |
| Welch Allyn | $19.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.